Join experts Manali Kamdar, a leader at the University of Colorado Cancer Center, Tycel Phillips from City of Hope, and Chan Cheah of Linear Clinical Research as they dive into the transformative role of BTK inhibitors in treating mantle cell lymphoma. They discuss groundbreaking trial results, including the SHINE trial, and the significance of tumor profiling in guiding treatment for high-risk patients. The panel also explores the shift away from chemotherapy towards targeted therapies and the exciting future options such as CAR-T cells and bispecific antibodies.
